NEW YORK--(BUSINESS WIRE)--Fitch Ratings has affirmed the 'A+' rating on the following bonds issued by the Massachusetts Development Finance Agency on behalf of Baystate Medical Center (Baystate):
--$55,115,000 revenue bonds, series N (2014).
In addition, Fitch affirms the 'A+' rating on Baystate's outstanding debt issued by the Massachusetts Health and Educational Facilities Authority, which is listed at the end of the press release.
The Rating Outlook is Stable.
The bonds are secured by the obligated group's gross receipts.
KEY RATING DRIVERS
LEADING MARKET POSITION AND INTEGRATED SERVICE NETWORK: Baystate's integrated delivery network includes four hospitals, employed medical groups, a health plan and a physician hospital organization. The integrated healthcare network bolsters Baystate's market profile in an evolving environment that is accelerating towards value-based care and population health management. As for Baystate's inpatient hospital market position, they secure a leading 56% share in a large three county primary service area, well more than twice the level of its nearest competitor.
LOW DEBT BURDEN: Baystate's maximum annual debt service (MADS) of approximately $33.37 million (excluding an $11.6 million balloon payment in 2026) amounts to a low 1.4% of revenues through nine months of the current fiscal year (year-end Sept. 30). As a result, despite the softer earnings and cash flow, MADS debt service coverage is very good at 4.9x for the unaudited nine month period ending June 30, 2016. Furthermore, MADS is projected to decline by about $4.7 million in fiscal 2017 since Baystate's new markets tax credit deal is expected to unwind and result in the forgiveness of debt.
WEAKER OPERATING PERFORMANCE: After stable operations from fiscal 2012-2014, profitability weakened during the past few years due to losses at a newly acquired hospital and employed medical groups, increased staffing and pharmacy costs at Baystate's hospitals, as well as operating challenges arising from expanded Medicaid enrollment at its health plan, Health New England. After falling to negative 0.5% and 3.3%, respectively in fiscal 2015, the operating and operating EBITDA margins improved to 1.8% and 5.4% (prior to one-time reduction in force costs), respectively during the first nine months of fiscal 2016.
SOFTENED LIQUIDITY METRICS: As of June 30, 2016, $803.6 million of cash and investments amounts to 131.1 days cash on hand (DCOH) and 139.7% of long-term debt, down from 175.4 DCOH and 171.4% cash to debt at the end of fiscal 2014. While the absolute liquidity levels have remained relatively stable, growth in the business base from acquisitions and health plan enrollment gains, as well as increased long-term debt are suppressing liquidity ratios.
OPERATING PERFORMANCE: While financial performance rebounded somewhat in the current fiscal year, operating challenges persist due to governmental payment reductions and expense pressures at both Baystate Health's delivery network and insurance operations. Fitch expects Baystate Health to make the necessary adjustments to maintain the improved performance nevertheless failure to meet budgeted operating targets may result in negative rating pressure.
LIQUIDITY STABILIZATION: Given Baystate Health's low debt burden and good debt service coverage, its cash position is satisfactory for the rating. However, any further softening of liquidity metrics could pressure the rating.
Baystate Health, Inc. is an integrated health care delivery system headquartered in Springfield, MA. Baystate Health, Inc. consists of four hospitals (including the 710-bed flagship, Baystate Medical Center), Baystate Medical Practices (a multi-specialty academic group practice with over 550 employed physicians), Health New England (a not-for-profit health maintenance organization with about 223,000 covered lives), a physician hospital organization and other ancillary health care entities. The obligated group only includes Baystate Medical Center and Baystate Total Home Care. Baystate Total Home Care holds a ground lease and real estate for Baystate Medical Center. On a consolidated basis, total revenues in fiscal 2015 (Sept. 30 year-end) were approximately $2.1 billion. The obligated group represents about 65% of total system assets and 53% of total system revenues. Fitch's analysis and the figures cited in this press release include the consolidated entity, Baystate Health, Inc.
Baystate's integrated delivery network has driven a successful regional expansion and a leading inpatient hospital market share in a large three county primary service area in west central Massachusetts. Complementing its multiple hospital locations, Baystate employs 550 physicians at more than 60 sites in and around Springfield, MA. Moreover, Baystate's ownership of Health New England rounds out its fully integrated network and provides them control of insurance premiums and enhanced population health capabilities.
While modest service area competition is evident, Baystate's ownership of the region's only academic tertiary hospital and Level I trauma center helps to stem outmigration and maintain a very good market position. The acquisition of Wing Hospital in 2014 and Noble Hospital in 2015 further solidified Baystate's market position in west central Massachusetts. On a combined basis, Baystate secured 56% inpatient market share (as of 2014, which is the most current data available). The next closest competitor was Mercy Medical Center (part of Trinity Health, rated 'AA-'/Negative Outlook), which held less than 20% inpatient market share.
After stable operations from fiscal 2012-2014, profitability weakened during the past few years due to losses at a newly acquired hospital and employed medical groups, rising staffing and pharmacy costs at Baystate's hospitals, as well operating challenges arising from expanded Medicaid enrollment from its health plan, Health New England. Specifically, Baystate Wing Hospital that was acquired in 2014 lost $5.1 million in fiscal 2015 and Baystate Medical Practices' losses increased by nearly $10 million in fiscal 2015. At the flagship Baystate Medical Center in fiscal 2015, operating earnings declined by about $17.5 million despite increased volumes as a result of a weaker payor mix and higher labor and pharmacy costs.
Health New England posed the greatest financial pressures during fiscal 2015 due to rapidly expanded Medicaid enrollment, which was subsequently reduced in the current fiscal year. As a result of the Commonwealth of Massachusetts' program expansion and a competing health plan's regional strategy, about 60,000 Medicaid enrollees switched to Health New England in fiscal 2015. Certain of these new enrollees were very high healthcare utilizers with chronic conditions. Therefore, these much higher costs caused Health New England's net income to dramatically decline to negative $28.2 million in fiscal 2015, from a gain of $3.9 million the prior fiscal year. Regardless, management quickly reacted and made the appropriate adjustments in the current fiscal year by dis-enrolling about 13,000 Medicaid enrollees, increasing premiums and renegotiating its pharmacy contract. As a result, Baystate's insurance operations produced a $3.76 million gain through the first nine months of fiscal 2016.
From a metric standpoint, after falling to negative 0.5% and 3.3%, respectively in fiscal 2015 (both metrics exclude a $69.65 million gain on pension curtailment), the operating and operating EBITDA margins improved to 1.8% and 5.4% (prior to one-time reduction in force costs), respectively during the first nine months of fiscal 2016. Management expects financial pressures to persist in fiscal 2017, mostly due to lower health plan rate increases, Medicaid rate reductions and the loss of the rural wage index classification from Medicare. As a result, Baystate closed its Mary Lane Hospital for inpatient services and consolidated its operations with Wing Hospital during September 2016, as well as instituted a reduction in force that is expected to decrease full-time equivalent employees by about 250 to 300 over the next several months. These cost reduction measures are expected to produce fiscal 2017 operating margins that are consistent with current year performance.
LIQUIDITY AND DEBT POSITION
Absolute liquidity levels have remained relatively stable, but growth in the business base from acquisitions and health plan enrollment gains, as well as increased long-term debt are suppressing liquidity ratios. As of June 30, 2016, $803.6 million of cash and investments amounts to 131.1 DCOH and 139.7% of long-term debt, down from 175.4 days operating expenses and 171.4% cash to debt at the end of fiscal 2014. Given Baystate Health's low debt burden and good debt service coverage, its cash position is satisfactory for the rating. However, any further softening of liquidity metrics could lead to rating pressure.
Baystate's total long-term debt (including current portion) increased to $575 million as of June 30, 2016, from $478 million at the end of fiscal 2014. Regardless, MADS of approximately $33.37 million (excluding an $11.6 million balloon payment in 2026) amounts to a low 1.4% of revenues for the nine month period ending June 30, 2016. Additionally, total long-term debt and MADS are most likely to decline by about $81 million and $4.7 million, respectively in fiscal 2017 since Baystate's new markets tax credit deal is expected to unwind and result in the forgiveness of debt.
Given the rising costs of running its pension, Baystate froze its defined benefit plan effective Dec. 31, 2015. The freeze was accounted for as a curtailment and resulted in a one-time credit to the net periodic pension cost of about $71.9 million. In addition, a curtailment gain of $47.9 million reduced the pension obligation and was recorded as an increase in unrestricted net assets. Nonetheless, the pension liability increased to $117 million in fiscal 2015 (for a manageable 88% funded status) from $99.5 million in fiscal 2014 since the fair value of the pension assets declined. Fitch views the pension freeze favorably since it provides expense savings, caps its long-term liabilities, and reduces variability in its financial position.
Outstanding Baystate debt issued by the Massachusetts Health and Educational Facilities Authority rated by Fitch as of Oct. 12, 2016:
--$43,345,000 revenue bonds, series G (2005)*;
--$5,487,000 revenue bonds, series M-4A (2005)*;
--$4,222,000 revenue bonds, series H (2007);
--$6,519,000 revenue bonds, series M-2 (2008)*;
--$63,380,000 revenue bonds, series I (2009);
--$45,000,000 revenue bonds, series J-1 (2009)*;
--$45,000,000 revenue bonds, series J-2 (2009)*;
--$20,045,000 revenue bonds, series K-1 (2009)*; and
--$26,365,000 revenue bonds, series K-2 (2009)*.
*These bonds are variable rate demand obligations supported by bank letters of credit.
Additional information is available at 'www.fitchratings.com'.
Revenue-Supported Rating Criteria (pub. 16 Jun 2014)
U.S. Nonprofit Hospitals and Health Systems Rating Criteria (pub. 09 Jun
Dodd-Frank Rating Information Disclosure Form
Copyright © 2016 by Fitch Ratings, Inc., Fitch Ratings Ltd. and its subsidiaries. 33 Whitehall Street, NY, NY 10004. Telephone: 1-800-753-4824, (212) 908-0500. Fax: (212) 480-4435. Reproduction or retransmission in whole or in part is prohibited except by permission. All rights reserved. In issuing and maintaining its ratings and in making other reports (including forecast information), Fitch relies on factual information it receives from issuers and underwriters and from other sources Fitch believes to be credible. Fitch conducts a reasonable investigation of the factual information relied upon by it in accordance with its ratings methodology, and obtains reasonable verification of that information from independent sources, to the extent such sources are available for a given security or in a given jurisdiction. The manner of Fitch's factual investigation and the scope of the third-party verification it obtains will vary depending on the nature of the rated security and its issuer, the requirements and practices in the jurisdiction in which the rated security is offered and sold and/or the issuer is located, the availability and nature of relevant public information, access to the management of the issuer and its advisers, the availability of pre-existing third-party verifications such as audit reports, agreed-upon procedures letters, appraisals, actuarial reports, engineering reports, legal opinions and other reports provided by third parties, the availability of independent and competent third-party verification sources with respect to the particular security or in the particular jurisdiction of the issuer, and a variety of other factors. Users of Fitch's ratings and reports should understand that neither an enhanced factual investigation nor any third-party verification can ensure that all of the information Fitch relies on in connection with a rating or a report will be accurate and complete. Ultimately, the issuer and its advisers are responsible for the accuracy of the information they provide to Fitch and to the market in offering documents and other reports. In issuing its ratings and its reports, Fitch must rely on the work of experts, including independent auditors with respect to financial statements and attorneys with respect to legal and tax matters. Further, ratings and forecasts of financial and other information are inherently forward-looking and embody assumptions and predictions about future events that by their nature cannot be verified as facts. As a result, despite any verification of current facts, ratings and forecasts can be affected by future events or conditions that were not anticipated at the time a rating or forecast was issued or affirmed.
The information in this report is provided "as is" without any representation or warranty of any kind, and Fitch does not represent or warrant that the report or any of its contents will meet any of the requirements of a recipient of the report. A Fitch rating is an opinion as to the creditworthiness of a security. This opinion and reports made by Fitch are based on established criteria and methodologies that Fitch is continuously evaluating and updating. Therefore, ratings and reports are the collective work product of Fitch and no individual, or group of individuals, is solely responsible for a rating or a report. The rating does not address the risk of loss due to risks other than credit risk, unless such risk is specifically mentioned. Fitch is not engaged in the offer or sale of any security. All Fitch reports have shared authorship. Individuals identified in a Fitch report were involved in, but are not solely responsible for, the opinions stated therein. The individuals are named for contact purposes only. A report providing a Fitch rating is neither a prospectus nor a substitute for the information assembled, verified and presented to investors by the issuer and its agents in connection with the sale of the securities. Ratings may be changed or withdrawn at any time for any reason in the sole discretion of Fitch. Fitch does not provide investment advice of any sort. Ratings are not a recommendation to buy, sell, or hold any security. Ratings do not comment on the adequacy of market price, the suitability of any security for a particular investor, or the tax-exempt nature or taxability of payments made in respect to any security. Fitch receives fees from issuers, insurers, guarantors, other obligors, and underwriters for rating securities. Such fees generally vary from US$1,000 to US$750,000 (or the applicable currency equivalent) per issue. In certain cases, Fitch will rate all or a number of issues issued by a particular issuer, or insured or guaranteed by a particular insurer or guarantor, for a single annual fee. Such fees are expected to vary from US$10,000 to US$1,500,000 (or the applicable currency equivalent). The assignment, publication, or dissemination of a rating by Fitch shall not constitute a consent by Fitch to use its name as an expert in connection with any registration statement filed under the United States securities laws, the Financial Services and Markets Act of 2000 of the United Kingdom, or the securities laws of any particular jurisdiction. Due to the relative efficiency of electronic publishing and distribution, Fitch research may be available to electronic subscribers up to three days earlier than to print subscribers.
For Australia, New Zealand, Taiwan and South Korea only: Fitch Australia Pty Ltd holds an Australian financial services license (AFS license no. 337123) which authorizes it to provide credit ratings to wholesale clients only. Credit ratings information published by Fitch is not intended to be used by persons who are retail clients within the meaning of the Corporations Act 2001